

FOR IMMEDIATE RELEASE

Contact:
Todd Aldrich
Tel 1-651-233-5948
taldrich@biomedix.com

PADnet™ Receives Patents for Vascular Testing System
Internet-Based Diagnostic Tool Designed for Primary Care

TWIN CITIES, MN - January 23 and February 6, 2007 – BioMedix Vascular Solutions has received two US Patent Awards for PADnet, a system designed to detect Peripheral Arterial Disease (PAD). The patented PADnet system, which received FDA marketing clearance in 2004, uploads physiologic test data from primary care test sites to a secure Internet site where expert readers interpret the tests and provide study interpretations. “By incorporating the standard ABI (ankle-brachial) exam along with this patented method of TBI (toe brachial) exams, as well as plethysmography, the PADnet Lab provides clinically useful data,” said Dr. Thomas Fogarty, a Medical Advisor to the company. The system is designed for staff in primary care settings. Previously, PAD tests generally required the services of technicians in vascular labs.

PAD is a condition in which fatty deposits build up on the inner linings of arteries, and restrict the flow of blood to muscles and organs, especially the kidneys, stomach, arms, legs and feet. More than 10 million Americans are afflicted with the disease, and without treatment, over 30% of these people will die within 5 years. PAD also accounts for about half of all amputations among diabetics, and it is the major cause of amputation for non-diabetic patients. Early diagnosis of PAD improves the chances of saving limbs and improving the quality of life. By extending diagnostic capabilities to primary care settings, BioMedix is dedicated to detecting more cases of PAD. To date the PADnet system has tested more than 35,000 patients.

Traditional diagnosis for PAD requires extensive training and technical skill. The most common physiologic test for PAD has consisted of a thorough pulse examination and verification of the ankle-brachial index (ABI). These processes require the use of a Doppler ultrasound probe to determine the return of pressure when blood flow to an artery is interrupted. BioMedix’s PADnet overcomes many issues associated with the use of conventional tests for PAD, including the highly technician dependent use of Doppler, and reliance on the ankle-brachial index (ABI) exam as a standalone test, which for some patients with stiff, non-compliant arteries does not produce useful data. John Romans, CEO of BioMedix, and one of the inventors, noted, “These patents are the culmination of a lot of work by many talented and committed individuals. PADnet is the key to a device and information platform of vascular diagnostic solutions for communities of care”.

About BioMedix, Inc.

BioMedix provides diagnostic solutions for vascular disease, a medical condition that kills or disfigures more than 875,000 Americans each year. Our innovative devices and software link primary care providers, vascular laboratories, vascular interventionalists, and health care systems. BioMedix is dedicated to prolonging and enhancing life through the early detection of vascular disease. BioMedix has the only integrated suite of products, software and online services that make it possible to get reimbursed for Peripheral Vascular Disease diagnostic tests in both specialist and primary care practices. We merge clinical data and patient demographics to provide a more complete picture of vascular health. We help eliminate mistakes, build revenue and provide data for sound analysis. For more information, logon to www.biomedix.com.

For more information about peripheral arterial disease, visit:

Society of Interventional Radiology

<http://www.sirweb.org/patPub/vascularOverview.shtml>

Vascular Disease Foundation

<http://www.vdf.org/>

The Cleveland Clinic

<http://www.clevelandclinicmeded.com/diseasemanagement/cardiology/pad/pad1.htm>

American Academy of Family Physicians

<http://www.aafp.org/afp/20040201/525.html>

###